Select Publications
Journal articles
2011, 'Laser-capture micro-dissection and gene array analysis to identify new molecules implicated in the development of myeloma bone disease', Bone, 48, pp. S19 - S19, http://dx.doi.org/10.1016/j.bone.2010.10.049
,2011, 'Mechanisms of osteoblast supression in multiple myeolma', Bone, 48, pp. S37 - S37, http://dx.doi.org/10.1016/j.bone.2010.10.103
,2011, 'Multiphoton imaging of individual myeloma cells in calvariae: Association of myeloma development with sites of bone turnover', Bone, 48, pp. S14 - S14, http://dx.doi.org/10.1016/j.bone.2010.10.037
,2011, 'Targeting tumour-initiating cells with trail based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo', Bone, 48, pp. S15 - S15, http://dx.doi.org/10.1016/j.bone.2010.10.040
,2010, 'Bisphosphonate therapy in the treatment of multiple myeloma', Current Pharmaceutical Design, 16, pp. 3028 - 3036, http://dx.doi.org/10.2174/138161210793563608
,2010, 'Metastasis and bone loss: Advancing treatment and prevention', Cancer Treatment Reviews, 36, pp. 615 - 620, http://dx.doi.org/10.1016/j.ctrv.2010.04.003
,2010, 'The Effect of Myeloma Cells on Bone Homeostasis Is Heterogenous and Correlates with Underlying Genetic Lesions and Bone Disease In Vivo', Blood, 116, pp. 4052 - 4052, http://dx.doi.org/10.1182/blood.v116.21.4052.4052
,2010, 'Alterations in the self-renewal and differentiation ability of bone marrow mesenchymal stem cells in a mouse model of rheumatoid arthritis', Arthritis Research and Therapy, 12, http://dx.doi.org/10.1186/ar3098
,2010, 'Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes', Leukemia Research, 34, pp. 742 - 751, http://dx.doi.org/10.1016/j.leukres.2009.10.016
,2010, 'Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts', Proceedings of the National Academy of Sciences of the United States of America, 107, pp. 7604 - 7609, http://dx.doi.org/10.1073/pnas.0911346107
,2010, 'Fas receptor is required for estrogen deficiency-induced bone loss in mice', Laboratory Investigation, 90, pp. 402 - 413, http://dx.doi.org/10.1038/labinvest.2009.144
,2010, 'Regulation of neural crest cell fate by the retinoic acid and Pparg signalling pathways', Development, 137, pp. 389 - 394, http://dx.doi.org/10.1242/dev.044164
,2010, 'Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo', Journal of Bone and Mineral Research, 25, pp. 2633 - 2646, http://dx.doi.org/10.1002/jbmr.142
,2010, 'Targeting RANK/RANKL in the treatment of solid tumours and myeloma', Current Pharmaceutical Design, 16, pp. 1272 - 1283, http://dx.doi.org/10.2174/138161210791034021
,2009, 'Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.', Blood, 114, pp. 298 - 298, http://dx.doi.org/10.1182/blood.v114.22.298.298
,2009, 'The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network', Annals of Oncology, 20, pp. 1303 - 1317, http://dx.doi.org/10.1093/annonc/mdn796
,2009, 'Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790', International Journal of Cancer, 125, pp. 1177 - 1185, http://dx.doi.org/10.1002/ijc.24436
,2009, 'Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: Effect on myeloma bone disease in the 5T2MM murine model of myeloma', Cancer Research, 69, pp. 5307 - 5311, http://dx.doi.org/10.1158/0008-5472.CAN-08-4472
,2009, 'Inhibiting dickkopf-1 (Dkkl) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma', Journal of Bone and Mineral Research, 24, pp. 425 - 436, http://dx.doi.org/10.1359/jbmr.081104
,2009, 'Tracking gene expression during zebrafish osteoblast differentiation', Developmental Dynamics, 238, pp. 459 - 466, http://dx.doi.org/10.1002/dvdy.21838
,2009, 'The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models', Leukemia, 23, pp. 1894 - 1903, http://dx.doi.org/10.1038/leu.2009.121
,2009, '13-P049 FGF signalling is regulating bone development in zebrafish', Mechanisms of Development, 126, pp. S209 - S209, http://dx.doi.org/10.1016/j.mod.2009.06.522
,2009, 'B144 The Effect of JNJ-26481585 in Murine Myeloma Models', Clinical Lymphoma and Myeloma, 9, pp. S104 - S104, http://dx.doi.org/10.1016/s1557-9190(11)70664-3
,2009, 'Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the formation of osteolytic bone disease in the 5T2MM murine model of myeloma', Bone, 44, pp. S55 - S55, http://dx.doi.org/10.1016/j.bone.2009.01.465
,2009, 'Genetic models of bone disease using ENU mutagenesis', Bone, 44, pp. S19 - S19, http://dx.doi.org/10.1016/j.bone.2009.01.041
,2009, 'Inhibiting glycogen synthase kinase-3 (GSK-3) prevents the development of myeloma bone disease', Bone, 44, pp. S53 - S54, http://dx.doi.org/10.1016/j.bone.2009.01.462
,2009, 'Localising individual myeloma cells to the myeloma ‘niche’ in bone using multiphoton microscopy', Bone, 44, pp. S164 - S164, http://dx.doi.org/10.1016/j.bone.2009.01.384
,2009, 'Soluble RANK ligand produced by myeloma cells contributes to generalised bone loss in multiple myeloma', Bone, 44, pp. S162 - S162, http://dx.doi.org/10.1016/j.bone.2009.01.458
,2009, 'Tracking gene expression during zebrafish osteoblast differentiation', Developmental Dynamics, 238, http://dx.doi.org/10.1002/dvdy.21904
,2008, 'Geranylgeranyl transferase type II inhibition prevents myeloma bone disease', Biochemical and Biophysical Research Communications, 377, pp. 453 - 457, http://dx.doi.org/10.1016/j.bbrc.2008.09.157
,2008, 'Erratum: The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis (Leukemia (2008) vol. 22 (2247-2256) 10.1038/ leu.2008.2256)', Leukemia, 22, pp. 2292, http://dx.doi.org/10.1038/leu.2008.288
,2008, 'Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension', American Journal of Pathology, 172, pp. 256 - 264, http://dx.doi.org/10.2353/ajpath.2008.070395
,2008, 'The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis', Leukemia, 22, pp. 2247 - 2256, http://dx.doi.org/10.1038/leu.2008.235
,2008, 'OC7. Inhibiting dickkopf-1 (Dkk-1) prevents the development of osteolytic bone disease in multiple myeloma', Cancer Treatment Reviews, 34, pp. 52 - 52, http://dx.doi.org/10.1016/j.ctrv.2008.03.033
,2008, 'P1. Breast cancer cells cause a reduction in osteoblast number – An early event in the development of osteolytic bone lesions', Cancer Treatment Reviews, 34, pp. 12 - 12, http://dx.doi.org/10.1016/j.ctrv.2008.03.042
,2008, 'P3. A soluble activin type II receptor prevents the development of myeloma bone disease', Cancer Treatment Reviews, 34, pp. 13 - 14, http://dx.doi.org/10.1016/j.ctrv.2008.03.044
,2007, 'In Vivo Evaluation of a BAFF Inhibitor AMG 523 Suggests Lack of Efficacy in Multiple Myeloma Tumor Models.', Blood, 110, pp. 1518 - 1518, http://dx.doi.org/10.1182/blood.v110.11.1518.1518
,2007, 'Investigating the interaction between osteoprotegerin and receptor activator of NF-κB or tumor necrosis factor-related apoptosis-inducing ligand: Evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways', Journal of Biological Chemistry, 282, pp. 31601 - 31609, http://dx.doi.org/10.1074/jbc.M706078200
,2007, 'Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: Beneficial effects on tumor growth, angiogenesis, bone disease and survival', International Journal of Cancer, 121, pp. 1857 - 1861, http://dx.doi.org/10.1002/ijc.22845
,2007, 'Myeloma bone disease and proteasome inhibition therapies', Blood, 110, pp. 1098 - 1104, http://dx.doi.org/10.1182/blood-2007-03-067710
,2007, 'Inhibition of p38α mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma', Cancer Research, 67, pp. 4572 - 4577, http://dx.doi.org/10.1158/0008-5472.CAN-06-4361
,2007, 'Apomine™, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo', International Journal of Cancer, 120, pp. 1657 - 1663, http://dx.doi.org/10.1002/ijc.22478
,2007, 'The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis', Journal of Immunology, 178, pp. 3379 - 3389, http://dx.doi.org/10.4049/jimmunol.178.6.3379
,2007, 'A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer', Leukemia, 21, pp. 2181 - 2191, http://dx.doi.org/10.1038/sj.leu.2404814
,2007, 'Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment', Leukemia, 21, pp. 805 - 812, http://dx.doi.org/10.1038/sj.leu.2404518
,2007, 'An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma', Cancer Research, 67, pp. 202 - 208, http://dx.doi.org/10.1158/0008-5472.CAN-06-1287
,2006, 'Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma', British Journal of Haematology, 135, pp. 688 - 692, http://dx.doi.org/10.1111/j.1365-2141.2006.06356.x
,2006, 'Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.', Blood, 108, pp. 506 - 506, http://dx.doi.org/10.1182/blood.v108.11.506.506
,2006, 'Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Inhibit Osteoclast Activation and Increase Trabecular Bone Area in a Xenogeneic Murine Model of Myeloma.', Blood, 108, pp. 505 - 505, http://dx.doi.org/10.1182/blood.v108.11.505.505
,2006, 'Inhibition of p38α MAPK Reduces Tumor Burden, Prevents the Development of Myeloma Bone Disease, and Increases Survival in the 5T2 and 5T33 Murine Models of Myeloma.', Blood, 108, pp. 3436 - 3436, http://dx.doi.org/10.1182/blood.v108.11.3436.3436
,